Sosei will receive upfront payment, potential near-term development milestones and research funding of up to £34 million (US$46 million) and could receive additional milestone payments of up to £336 million (US$454 million).
The company said the COVID-19 pandemic has disrupted vaccination rates, particularly for its blockbuster shingles vaccine, Shingrix, which was the biggest sales growth driver last year.
